105289A first-in-patient trial of TenoMiR a microRNA replacement therapy for tendinopathy.ClosedCollaborative R&DInnovate UK"One in 10 people will suffer from some form of tendinopathy during their lifetime, yet currently, the best treatment remains physiotherapy which only benefits 50% of cases. Despite recent advances in biological therapy, there remains no effective treatment for tendinopathy. Research at Causeway Therapeutics uncovered the molecular mechanism that causes damaged tendons to develop tendinopathy. This insight led to the development of TenoMiR that directly targets the key features of the disease. Treatment with TenoMiR effectively restores tendon structure and function. Causeway Therapeutics' objective is to develop the world's first microRNA therapy revolutionising the treatment of soft tissue tendon injuries. This grant will allow Causeway to demonstrate TenoMiR's safety and effectiveness in patients suffering from tendinopathy."